Grand Pharmaceutical Group Limited

SEHK:512 Stok Raporu

Piyasa değeri: HK$16.0b

Grand Pharmaceutical Group Yönetim

Yönetim kriter kontrolleri 3/4

Grand Pharmaceutical Group's CEO is Chao Zhou, appointed in Jun 2021, has a tenure of 3.42 years. total yearly compensation is HK$1.87M, comprised of 90.8% salary and 9.2% bonuses, including company stock and options. directly owns 0.01% of the company’s shares, worth HK$1.62M. The average tenure of the management team and the board of directors is 3.4 years and 3.4 years respectively.

Anahtar bilgiler

Chao Zhou

İcra Kurulu Başkanı

HK$1.9m

Toplam tazminat

CEO maaş yüzdesi90.8%
CEO görev süresi3.4yrs
CEO sahipliği0.01%
Yönetim ortalama görev süresi3.4yrs
Yönetim Kurulu ortalama görev süresi3.4yrs

Son yönetim güncellemeleri

Recent updates

Grand Pharmaceutical Group Limited (HKG:512) Looks Inexpensive But Perhaps Not Attractive Enough

Sep 19
Grand Pharmaceutical Group Limited (HKG:512) Looks Inexpensive But Perhaps Not Attractive Enough

Grand Pharmaceutical Group (HKG:512) Is Paying Out A Larger Dividend Than Last Year

Jun 05
Grand Pharmaceutical Group (HKG:512) Is Paying Out A Larger Dividend Than Last Year

Market Participants Recognise Grand Pharmaceutical Group Limited's (HKG:512) Earnings

May 22
Market Participants Recognise Grand Pharmaceutical Group Limited's (HKG:512) Earnings

Grand Pharmaceutical Group (HKG:512) Will Pay A Larger Dividend Than Last Year At HK$0.26

Apr 25
Grand Pharmaceutical Group (HKG:512) Will Pay A Larger Dividend Than Last Year At HK$0.26

Grand Pharmaceutical Group (HKG:512) Will Pay A Larger Dividend Than Last Year At HK$0.26

Mar 25
Grand Pharmaceutical Group (HKG:512) Will Pay A Larger Dividend Than Last Year At HK$0.26

We Think Grand Pharmaceutical Group (HKG:512) Can Stay On Top Of Its Debt

Oct 20
We Think Grand Pharmaceutical Group (HKG:512) Can Stay On Top Of Its Debt

Here's Why We Think Grand Pharmaceutical Group (HKG:512) Is Well Worth Watching

Sep 26
Here's Why We Think Grand Pharmaceutical Group (HKG:512) Is Well Worth Watching

Grand Pharmaceutical Group's (HKG:512) Dividend Will Be Increased To HK$0.14

Jun 04
Grand Pharmaceutical Group's (HKG:512) Dividend Will Be Increased To HK$0.14

Is Grand Pharmaceutical Group (HKG:512) A Risky Investment?

May 05
Is Grand Pharmaceutical Group (HKG:512) A Risky Investment?

Grand Pharmaceutical Group (HKG:512) Seems To Use Debt Quite Sensibly

Nov 21
Grand Pharmaceutical Group (HKG:512) Seems To Use Debt Quite Sensibly

Is Grand Pharmaceutical Group Limited (HKG:512) Trading At A 43% Discount?

Sep 05
Is Grand Pharmaceutical Group Limited (HKG:512) Trading At A 43% Discount?

Grand Pharmaceutical Group (HKG:512) Seems To Use Debt Quite Sensibly

Aug 16
Grand Pharmaceutical Group (HKG:512) Seems To Use Debt Quite Sensibly

Here's Why We Think Grand Pharmaceutical Group (HKG:512) Is Well Worth Watching

Jul 28
Here's Why We Think Grand Pharmaceutical Group (HKG:512) Is Well Worth Watching

Grand Pharmaceutical Group's (HKG:512) Dividend Will Be HK$0.11

May 29
Grand Pharmaceutical Group's (HKG:512) Dividend Will Be HK$0.11

Is Grand Pharmaceutical Group Limited (HKG:512) Trading At A 45% Discount?

Apr 08
Is Grand Pharmaceutical Group Limited (HKG:512) Trading At A 45% Discount?

Grand Pharmaceutical Group (HKG:512) Has A Rock Solid Balance Sheet

Mar 22
Grand Pharmaceutical Group (HKG:512) Has A Rock Solid Balance Sheet

If You Like EPS Growth Then Check Out Grand Pharmaceutical Group (HKG:512) Before It's Too Late

Jan 24
If You Like EPS Growth Then Check Out Grand Pharmaceutical Group (HKG:512) Before It's Too Late

These 4 Measures Indicate That Grand Pharmaceutical Group (HKG:512) Is Using Debt Safely

Dec 13
These 4 Measures Indicate That Grand Pharmaceutical Group (HKG:512) Is Using Debt Safely

Grand Pharmaceutical Group Limited's (HKG:512) Intrinsic Value Is Potentially 45% Above Its Share Price

Nov 27
Grand Pharmaceutical Group Limited's (HKG:512) Intrinsic Value Is Potentially 45% Above Its Share Price

With EPS Growth And More, China Grand Pharmaceutical and Healthcare Holdings (HKG:512) Is Interesting

Oct 25
With EPS Growth And More, China Grand Pharmaceutical and Healthcare Holdings (HKG:512) Is Interesting

China Grand Pharmaceutical and Healthcare Holdings (HKG:512) Seems To Use Debt Rather Sparingly

Sep 01
China Grand Pharmaceutical and Healthcare Holdings (HKG:512) Seems To Use Debt Rather Sparingly

Do China Grand Pharmaceutical and Healthcare Holdings's (HKG:512) Earnings Warrant Your Attention?

Jul 12
Do China Grand Pharmaceutical and Healthcare Holdings's (HKG:512) Earnings Warrant Your Attention?

CEO Tazminat Analizi

Chao Zhou'un ücretlendirmesi Grand Pharmaceutical Group'un kazancına kıyasla nasıl değişti?
TarihToplam TazminatMaaşŞirket Kazançları
Jun 30 2024n/an/a

HK$2b

Mar 31 2024n/an/a

HK$2b

Dec 31 2023HK$2mHK$2m

HK$2b

Tazminat ve Piyasa: Chao's total compensation ($USD240.97K) is below average for companies of similar size in the Hong Kong market ($USD496.15K).

Tazminat ve Kazançlar: Insufficient data to compare Chao's compensation with company performance.


CEO

Chao Zhou (34 yo)

3.4yrs

Görev süresi

HK$1,873,000

Tazminat

Mr. Chao Zhou serves as Chief Executive Officer of Grand Pharmaceutical Group Limited (formerly known as China Grand Pharmaceutical and Healthcare Holdings Limited) since June 01, 2021 and serves as its Ex...


Liderlik Ekibi

İsimPozisyonGörev süresiTazminatSahiplik
Weikun Tang
Executive Chairman3.4yrsHK$2.89m0.021%
HK$ 3.3m
Chao Zhou
CEO & Executive Director3.4yrsHK$1.87m0.010%
HK$ 1.6m
Guang Yang
Executive Director1.4yrsHK$25.00kVeri yok
Liu Hu
Investor Relations Directorno dataVeri yokVeri yok
Chit Lam
Executive Directorless than a yearVeri yok0.017%
HK$ 2.6m
Tin Chung Foo
Company Secretary13.2yrsVeri yokVeri yok
Xiaofeng Shi
Chairman of Grand Pharm (China)no dataVeri yokVeri yok
Xiaojie Chen
Vice Presidentno dataVeri yokVeri yok

3.4yrs

Ortalama Görev Süresi

51yo

Ortalama Yaş

Deneyimli Yönetim: 512's management team is considered experienced (3.4 years average tenure).


Yönetim Kurulu Üyeleri

İsimPozisyonGörev süresiTazminatSahiplik
Weikun Tang
Executive Chairman3.4yrsHK$2.89m0.021%
HK$ 3.3m
Chao Zhou
CEO & Executive Director1.4yrsHK$1.87m0.010%
HK$ 1.6m
Guang Yang
Executive Director1.4yrsHK$25.00kVeri yok
Chit Lam
Executive Directorless than a yearVeri yok0.017%
HK$ 2.6m
Xiaofeng Shi
Chairman of Grand Pharm (China)no dataVeri yokVeri yok
Tosi Wan So
Independent Non-Executive Director19.7yrsHK$180.00kVeri yok
Yebi Hu
Independent Non-Executive Director5.9yrsHK$60.00kVeri yok
Geng Pei
Independent Non-Executive Director13.5yrsHK$100.00kVeri yok
Guofan Xie
Director of Grand Pharm (China)30.8yrsVeri yokVeri yok
Zhang Bangguo
Director of Zhejiang Xianju Xianle Pharmaceutical Company Limitedno dataVeri yokVeri yok
Li Xing
Non-Executive Directorless than a yearVeri yokVeri yok

3.4yrs

Ortalama Görev Süresi

57yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: 512's board of directors are considered experienced (3.4 years average tenure).